Gastroesophageal Reflux Disease Management

Introduction to GERD Management

The American Gastroenterological Association recommends tapering rather than abrupt discontinuation of medication for patients with GERD to minimize unnecessary medication exposure and potential side effects 1
Maintaining the full therapeutic dose long-term without attempting to taper exposes the patient to unnecessary medication and potential side effects, according to the American Gastroenterological Association 1

Testing for H. pylori is not indicated for typical GERD that has responded to PPI therapy, but would be more appropriate for patients with peptic ulcer disease or uninvestigated dyspepsia 2
If symptoms recur with tapering, consider diagnostic testing with endoscopy or prolonged wireless pH monitoring to confirm GERD diagnosis, as recommended by the American Gastroenterological Association 3
Prolonged wireless pH monitoring can determine the presence and severity of GERD, with criteria for: 3

On-demand therapy, using PPIs as needed rather than continuously, can be an effective maintenance strategy for some patients with GERD, as suggested by the American Gastroenterological Association 1
A 4-8 week trial of single-dose proton pump inhibitor (PPI) therapy is recommended for patients with typical reflux symptoms, with standard doses:
PPI Standard Dose
Omeprazole 20 mg once daily
Lansoprazole 30 mg once daily
Pantoprazole 40 mg once daily
Rabeprazole 20 mg once daily
3, 4, 5
The American Gastroenterological Association recommends tapering PPIs to the lowest effective dose after achieving adequate response to initial therapy, balancing symptom control with minimizing unnecessary long-term PPI exposure 3
Patients should be advised that they may experience temporary upper GI symptoms after PPI dose reduction due to rebound acid hypersecretion (RAHS), which does not necessarily indicate treatment failure, according to the American Gastroenterological Association 1
If symptoms recur during tapering, returning to the previous effective dose is recommended by the American Gastroenterological Association 1

The American Society for Gastrointestinal Endoscopy recommends considering surgical or endoscopic anti-reflux procedures, such as laparoscopic fundoplication, magnetic sphincter augmentation, or transoral incisionless fundoplication, for patients who do not respond to PPI therapy 3
Surgical treatment options may be considered for proven GERD with inadequate response to medical therapy, as recommended by the American Gastroenterological Association 3

Weight management, elevating the head of the bed, and avoiding meals within 3 hours of bedtime are recommended lifestyle modifications for overweight or obese patients with GERD, as suggested by the American Gastroenterological Association 4
Avoiding specific trigger foods based on patient history is also recommended by the American Gastroenterological Association for patients with GERD 4
Frequent smaller meals that are low in fat and fiber content can help manage symptoms, as recommended by the American Gastroenterological Association 6

Patients with prior pyloroplasty may experience bile reflux, which is less responsive to acid suppression alone, according to the American Gastroenterological Association 7
Gastroparesis can exacerbate GERD symptoms by delaying gastric emptying, increasing intragastric pressure, and promoting reflux, as stated by the American Gastroenterological Association 6
Cholecystectomy can contribute to bile reflux, which may be less responsive to acid suppression alone, in patients with a history of cholecystectomy, as suggested by the American College of Gastroenterology 8
Dose adjustments are recommended for patients with severe liver impairment, hepatic impairment, or end-stage renal disease (ESRD) 9, 3

For PPI-refractory GERD, the American College of Gastroenterology recommends esomeprazole 40 mg twice daily for 8-12 weeks to achieve optimal acid suppression and symptom control 10
Alginate-containing antacids can help localize and displace the postprandial acid pocket, according to the American Gastroenterological Association 7
Baclofen (GABA agonist) may be beneficial for regurgitation symptoms but has side effects including somnolence and dizziness, as noted by the American Gastroenterological Association 7
Prokinetic agents, such as metoclopramide, domperidone, or erythromycin, can be added to address gastroparesis, as recommended by the American Gastroenterological Association 6
Gastric electric stimulation may be considered for severe cases with documented gastroparesis, as stated by the American Gastroenterological Association 6
Long-term PPI use is associated with increased risk of cardiovascular disease in patients with existing cardiovascular risk factors, making dose reduction or discontinuation important, as recommended by the American Gastroenterological Association 11, 3